Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate

September 25, 2020 -- Interim analysis from the ongoing Phase 1/2a clinical trial of the Janssen COVID-19 vaccine candidate (JNJ-78436735) was posted today on the pre-print server medRxiv. The data demonstrate that a single dose of JNJ-78436735...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials